1. High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes 
Tania Kaprealian, M.D., Vivian Weinberg, Ph.D., Joycelyn L. Speight, M.D., Ph.D., Alexander R. Gottschalk, M.D., Ph.D., Mack Roach, M.D., Katsuto Shinohara, M.D., I.-Chow Hsu, M.D. 
International Journal of Radiation Oncology • Biology • Physics 
Volume 82, Issue 1, Pages (January 2012)
DOI: /j.ijrobp
Copyright © Terms and Conditions

2. Fig. 1
Biochemical no-evidence-of-disease (bNED) rate by fractionation at 5-year follow-up. Solid line = 600 cGy × 3 (group 1) and a 5-year bNED rate of 93.5%. Dashed line = 950 cGy × 2 (group 2) and 5-year bNED rate of 87.3% (p = 0.19).
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © Terms and Conditions

3. Fig. 2
Progression-free survival (PFS) rate by fractionation at 5-year follow-up. Solid line = 600 cGy × 3 (group 1) and 5-year PFS rate of 86%. Dashed line = 950 cGy × 2 (group 2) and 5-year PFS rate of 83% (p = 0.53).
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © Terms and Conditions

4. Fig. 3
Progression-free survival (PFS) rate by the number of high-risk features with 600 cGy × 3 HDR boost. Number of failures/total number of patients at 5-year PFS: solid line = none; 3/26 patients; 92%. Dashed line 1 = 11/29 patients; 79%. Dotted lines 2 and 3 = 2/9 patients; 89% (p = 0.13).
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © Terms and Conditions

5. Fig. 4
PFS rate by the number of high-risk features with 950 cGy × 2 HDR boost. Number of failures/total number of patients at 5-year PFS. Solid line = none; 1/23 patients; 95%. Dashed line 1 = 7/44 patients; 81%. Dotted lines 2 and 3 = 6/34 patients; 77% (p = 0.45).
International Journal of Radiation Oncology • Biology • Physics  , DOI: ( /j.ijrobp )
Copyright © Terms and Conditions